ClinicalTrials.gg

TargetBeta

SLC12A1

solute carrier family 12 member 1 · also NKCC2, CCC2, BSC1, BSC · Solute carrier family 12

2 programs in company-led studies act on SLC12A1, from 2 companies: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
FurosemideruleBoehringer Ingelheimphase 4271 running–ChEMBL
TorsemideruleSarfez Pharmaceuticalsphase 4131 running–ChEMBL

Conditions their studies are in

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.